201341-05-1 Usage
Description
Tenofovir disoproxil is a prodrug belonging to the class of antiretroviral medications known as nucleotide reverse transcriptase inhibitors. It is structurally similar to abacavir and adefovir dipivoxil. The active drug is released after the phosphate-protecting groups are cleaved by plasma and tissue esterases. Tenofovir disoproxil exhibits good bioavailability, which is further improved in the presence of food. It is primarily used for the treatment of HIV infections in adult patients and is also effective in treating chronic hepatitis B. The drug works by blocking reverse transcriptase, an enzyme essential for viral replication in HIV-infected individuals. However, it does not cure HIV/AIDS or hepatitis B but helps lower the viral load and slow down the progression of the disease.
Uses
Used in HIV Treatment:
Tenofovir disoproxil is used as an antiretroviral agent for the treatment of HIV infections in adult patients. It is typically administered in combination with other reverse transcriptase inhibitors or protease inhibitors to achieve synergistic activity and improve treatment outcomes.
Used in Hepatitis B Treatment:
Tenofovir disoproxil is also used for the treatment of chronic hepatitis B, where it helps inhibit the enzymes required for the hepatitis B virus to reproduce, thus preventing the virus from multiplying and slowing down the progression of the disease.
Used as an Intermediate in Synthesis:
Tenofovir disoproxil serves as an intermediate in the synthesis of Tenofovir Disoproxil Dimer (T018515), which is a Tenofovir Disoproxil impurity. This application is relevant in the pharmaceutical industry for the development and production of related compounds and drugs.
Used in Pre-Exposure Prophylaxis (PrEP):
Tenofovir disoproxil can be used for prevention of HIV/AIDS among individuals at high risk before exposure, such as through sexual transmission or injection drug use. It functions by reducing the chances of acquiring the HIV infection when used as part of a comprehensive prevention strategy.
References
https://en.wikipedia.org/wiki/Tenofovir_disoproxil
http://bodyandhealth.canada.com/drug/getdrug/viread
https://www.drugbank.ca/drugs/DB00300
Clinical Use
Nucleoside reverse transcriptase inhibitor:
Treatment of HIV in combination with other
antiretroviral drugs
Treatment of hepatitis B in compensated liver
disease
Drug interactions
Potentially hazardous interactions with other drugs
Antivirals: avoid with adefovir and cidofovir; reduces
concentration of atazanavir, also concentration of
tenofovir possibly increased; increased didanosine
concentration resulting in increased toxicity
(e.g. pancreatitis and lactic acidosis) - avoid;
concentration increased by lopinavir and telaprevir.
Co-administration with other drugs that are actively
secreted via the tubular anionic transporter.
Orlistat: absorption possibly reduced by orlistat.
Metabolism
Tenofovir is excreted mainly in the urine by both active
tubular secretion and glomerular filtration.
Check Digit Verification of cas no
The CAS Registry Mumber 201341-05-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,1,3,4 and 1 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 201341-05:
(8*2)+(7*0)+(6*1)+(5*3)+(4*4)+(3*1)+(2*0)+(1*5)=61
61 % 10 = 1
So 201341-05-1 is a valid CAS Registry Number.
InChI:InChI=1/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1
201341-05-1Relevant articles and documents
Green synthesis improvement of tenofovir disoproxil
Wang, Gang,Xie, Yong Mei,Wang, Xing Hua
, p. S255 - S258 (2014)
Polyethylene glycol, known as 'Green Chemical', is a catalyst for the synthesis of tenofovir disoproxil. Some technological parameters were discussed by adoptting via single-factor experiments. Through the catalytic reaction, not only tenofovir disoproxil yield was improved but also by-products was reduced obviously. The results showed that the optimal conditions were as follows: 0.6 equiv PEG-600, 4.0 equiv triethylamine, 6.0 equiv N-methyl-2-pyrrolidone and temperature at 50°C for 16 h with a yield of 65.12 %.
Synthesis process of antiviral drug
-
Paragraph 0050-0063, (2020/11/26)
The invention discloses a synthesis process of an antiviral drug. The process comprises the following steps: reacting adenine (II) with (R)- propylene carbonate (III) to prepare a compound IV, carrying out alkylation reaction on the compound IV and a compound V to prepare a compound VI, and carrying out esterolysis reaction to prepare a compound VII; and carrying out esterification reaction on theprepared compound VII and chloromethyl isopropyl carbonate, and salifying with fumaric acid to prepare the final product tenofovir disoproxil fumarate (I). The synthetic route is simple, the reactionconditions are mild, the generation of impurities is reduced, the total yield and purity of the product are improved, and the method is suitable for industrial production.
A [...] and its preparation method for
-
Paragraph 0050; 0056; 0061; 0062; 0067; 0073, (2019/01/16)
The invention relates to the technical field of medicinal chemical engineering and particularly relates to a tenofovir disoproxil crystal form and a preparation method thereof. The tenofovir disoproxil has characteristic peaks when a diffraction angle 2[theta] is 7.3 +/- 0.2 degrees, 12.9 +/- 0.2 degrees, 14.4 +/- 0.2 degrees, 17.9 +/- 0.2 degrees, 19.1 +/- 0.2 degrees, 20.8 +/- 0.2 degrees and 22.9 +/- 0.2 degrees.
